Drug Trial Radar · NCT06397508
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Apr 2, 2024
Primary completion
May 8, 2024
Study completion May 13, 2024
Sponsor
- Lead sponsor
- Agomab Spain S.L.Industry
- Sponsor type
- Industry
- First posted
- May 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, single-dose, randomized, 3-period cross-over, Phase 1 study in healthy adult participants to assess the BA of AGMB-129 tablet formulation relative to that of the reference capsule formulation and to assess the effect of food on the BA of a single oral dose of the AGMB-129 tablet formulation. A total of 24 participants will be enrolled. Participants will be randomized to 1 of 6 intervention sequences (Williams design) according to a 6-sequence, 3-period design. In 3 sequential intervention periods, each participant will receive 3 study interventions, 1 in each intervention period. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.
Conditions
- Healthy Volunteers
Interventions
AGMB-129Drug
Each participant will receive 3 study interventions, 1 in each intervention period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax for AGMB-129Time frame: From baseline to Day 3
- Cmax for MET-158Time frame: From baseline to Day 3
- Cmax for MET-154Time frame: From baseline to Day 3
- AUC0-t for AGMB-129Time frame: From baseline to Day 3
- AUC0-t for MET-158Time frame: From baseline to Day 3
- AUC0-t for MET-154Time frame: From baseline to Day 3
- AUC0-∞ for AGMB-447Time frame: From baseline to Day 3
- AUC0-∞ for MET-158Time frame: From baseline to Day 3
- AUC0-∞ for MET-154Time frame: From baseline to Day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Belgium
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.